Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varespladib IV followed by Oral for Snakebite (BRAVIO)
NCT05717062Phase 2Completed
- Sponsor
- Ophirex
- Start
- May 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of varespladib in snakebite envenoming, sponsored by Ophirex. Started May 2023; status: completed.
02
Drugs
varespladib
03
Conditions
snakebite envenoming
Beyond the preview
Go deeper on NCT05717062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05717062.